Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 5 Publications

3 Customer Reviews

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC NFK5dFlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkS3bY5pcWKrdIOgeIhmKF[HR1[tbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIFjVWmVEew>? MofxNVg3OjB|OEK=
HUVEC NFe4fIVMcW6jc3WgZZN{[Xl? NGCwT2ZqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTNTJiaX6gTHVXTUNiY3XscJMhf2m2aDDhckBKSzVyIH;mJQKJxDhibl2= MWCxPFYzODN6Mh?=
MM M17LZmtqdmG|ZTDhd5NigQ>? MkTubY5pcWKrdIOgWmVITi2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCobISx NGXJSlYyPzF4NEOzNi=>
MM.1S M{PCO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml\LNVAh|rypL33M MnzibY5pcWKrdIOgUW0hS2WubDDHdo94fGh? M33GdFE4OTZ2M{Oy
MM.1R M2rOZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NI\3OYwyOCEQvHevcWw> NWWyPJc{cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MYexO|E3PDN|Mh?=
RPMI MnXoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnLNNVAh|rypL33M MmW4bY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MYCxO|E3PDN|Mh?=
Dox40 NXmzOo1WT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWmxNEDPxGdxbVy= MmfabY5pcWKrdIOgUW0hS2WubDDHdo94fGh? M2LpTFE4OTZ2M{Oy
INA-6 NHO2V|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3rMbVExKM7:Zz;tUC=> NXz6R3UxcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= NXjGUZRROTdzNkSzN|I>
OPM2 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHHK[YIyOCEQvHevcWw> NV\IPYhGcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MoHrNVcyPjR|M{K=
U266 M{fRNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmnGNVAh|rypL33M NETkWXRqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MmO2NVcyPjR|M{K=
MM.1S MX3jfZRwfG:6aXPpeJkh[XO|YYm= M1fHfVIxKM7:Zz;tUC=> MlXrbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= MUixO|E3PDN|Mh?=
MM.1R NVn4e2kx[3m2b4TvfIlkcXS7IHHzd4F6 NVnYR3dIOjBizsznM41N MkmzbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= M4rPNlE4OTZ2M{Oy
RPMI NIXhVmVkgXSxdH;4bYNqfHliYYPzZZk> NX3VNpl1OjBizsznM41N MnTFbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= MYGxO|E3PDN|Mh?=
Dox40 MorMZ5l1d3SxeHnjbZR6KGG|c3H5 NFzlSJgzOCEQvHevcWw> MYPpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MUixO|E3PDN|Mh?=
INA-6 M4XvToN6fG:2b4jpZ4l1gSCjc4PhfS=> MWWyNEDPxGdxbVy= MXrpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MnjJNVcyPjR|M{K=
OPM2 M4HPe4N6fG:2b4jpZ4l1gSCjc4PhfS=> MnO3NlAh|rypL33M NHS0d3hqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MnjKNVcyPjR|M{K=
U266 MlPMZ5l1d3SxeHnjbZR6KGG|c3H5 NWPYeGpHOjBizsznM41N MlTKbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NFuwe5IyPzF4NEOzNi=>
MM.1S NWTMPYZFTnWwY4Tpc44h[XO|YYm= NVjCfHNZe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u M{fBXlE4OTZ2M{Oy
MM.1R NFjvfVRHfW6ldHnvckBie3OjeR?= NWDo[XdWe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u M4XSTVE4OTZ2M{Oy
Dox40 NGP3UotHfW6ldHnvckBie3OjeR?= MVrzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? Mli4NVcyPjR|M{K=
OPM2 MkLOSpVv[3Srb36gZZN{[Xl? MnSxd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w MlHrNVcyPjR|M{K=
HBMEC MnznS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mnf1glExKM7:TR?= NFXDTJVFVVOR M{LkNGlEPTB;MTFOwG0> MXiyNVA5OTZ3Nh?=
HBMEC NVjiPGtnTnWwY4Tpc44h[XO|YYm= MV7+NUDPxE1? NXjNRopmTE2VTx?= NW[3b212[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= M1TXeFIyODhzNkW2
HBMEC MY\GeY5kfGmxbjDhd5NigQ>? MmS4glEh|ryP NXT6UpM6TE2VTx?= M4nvUIRqe3K3cITzJJRp\SCUYYOtVoFnNUWUSzDwZZRpf2G7IITodo92\2hiZHXjdoVie2WmIIDoc5NxcG:{eXzheIVlKE2HS{GvNkBidmRiRWLLNU8z NFnKPI8zOTB6MU[1Oi=>
HBMEC M3nkSGZ2dmO2aX;uJIF{e2G7 M{fNPJ4zOCEQvF2= MmXFSG1UVw>? NULBcHQy\Gm|coXweJMhPTBnIH;mJJR2[mViZn;ycYF1cW:wIHH0JFEh|ryP NYLGRVc1OjFyOEG2OVY>
MDA-MB-231 NVPqfIlJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mm\RglExKM7:TR?= NGjDdY5FVVOR M4\adGlEPTB;NTFOwG0> NEfsbVYzOTB6MU[1Oi=>
MDA-MB-231 NYS5UJF2TnWwY4Tpc44h[XO|YYm= M{eyZVAvPSEQvF2= NEXyTGVFVVOR NX7D[VducW6qaXLpeJMhfGinIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigQ>? Mk[zNlExQDF4NU[=
MDA-MB-231 Mkj6SpVv[3Srb36gZZN{[Xl? NUWzdJFKPSEQvF2= MXXEUXNQ M33pXolv\HWlZYOgZUBk\WyuLXP5Z4xmKGG{cnXzeC=> M1\Q[VIyODhzNkW2
J82 Mm\MZ5l1d3SxeHnjbZR6KGG|c3H5 NIPBZVB,OTBizszN MojLSG1UVw>? NUnZc2JCUUN3ME2yOE42PyEQvF2= MYOyNVUzQTlyMB?=
T24 MoPyZ5l1d3SxeHnjbZR6KGG|c3H5 NXHBT29rhjFyIN88US=> M3v3W2ROW09? MWDJR|UxRTV{LkS1JO69VQ>? NIDwZmYzOTV{OUmwNC=>
HT1376 M{TqNYN6fG:2b4jpZ4l1gSCjc4PhfS=> MnXPglExKM7:TR?= NIjKWppFVVOR MULJR|UxRTJ6LkKxJO69VQ>? NWmyTHF[OjF3Mkm5NFA>
RT4 NFnDWI1kgXSxdH;4bYNqfHliYYPzZZk> MlzIglExKM7:TR?= M1y1V2ROW09? M3XLNGlEPTB;NT6xOEDPxE1? NXzPT2tHOjF3Mkm5NFA>
CRL1749 Mmn5Z5l1d3SxeHnjbZR6KGG|c3H5 M1e3Tp4yOCEQvF2= M3vpO2ROW09? NUTTb4JOUUN3ME2yNk43QSEQvF2= MWiyNVUzQTlyMB?=
HTB9 M{LlZ4N6fG:2b4jpZ4l1gSCjc4PhfS=> NYDjTZl3hjFyIN88US=> MonCSG1UVw>? MX7JR|UxRTFzLki0JO69VQ>? MmHLNlE2Ojl7MEC=
Sup MnnnZ5l1d3SxeHnjbZR6KGG|c3H5 M{nGWp4yOCEQvF2= NIPP[2lFVVOR NVfEOWVzUUN3ME21N{4{OiEQvF2= NV63b5E1OjF3Mkm5NFA>
HTB3 M4S5OoN6fG:2b4jpZ4l1gSCjc4PhfS=> MXv+NVAh|ryP MlP1SG1UVw>? NE\EWI9KSzVyPUG0MlE3KM7:TR?= NXXxVmVROjF3Mkm5NFA>
CEC MkHFSpVv[3Srb36gZZN{[Xl? MUj+NVAh|rypL33M M3;zfmROW09? M2TXZoRwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz MmXuNlE3OjB6MkK=
RPE MYPGeY5kfGmxbjDhd5NigQ>? NEjMS5B,OTBizsznM41N M3X6dWROW09? NH3veJBld3ewLYLl[5Vt[XSnczDWSWdHKGyndnXsdy=> Mn7INlE3OjB6MkK=
CEC NXGwbXRxTnWwY4Tpc44h[XO|YYm= MU\+OUDPxGdxbVy= MVjEUXNQ NIHzNXRjdG:la4Og[Y5ld3SqZXzpZYwh[2WubDDtbYdz[XSrb36= MUKyNVYzODh{Mh?=
5637 MnfBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIPPXpFFVVOR NVH5WmN6UUN3ME2xOU4x6oDLzszN MmTnNlM5QDd4MEW=
J82 NEXaPGJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmPoSG1UVw>? MV;JR|UxRTF6LkVihKnPxE1? M4PaWFI{QDh5NkC1
5637 MkPuRZV1d3CqYXf5JIF{e2G7 M1rXOlIxKM7:TR?= M3nHcWROW09? MmXueJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? NXrtdFdlOjN6OEe2NFU>
J82 M3TZZmF2fG:yaHHnfUBie3OjeR?= MUeyNEDPxE1? M2jCcWROW09? NHS4UGh1emmpZ3Xyd{B1cGViYYX0c5Bp[WerYzDwdo9k\XO| M3fvXVI{QDh5NkC1
5637 NU\XT5dkTnWwY4Tpc44h[XO|YYm= MYWyNEDPxE1? NWHvdHh[TE2VTx?= MVzpcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO= NGHuZW0zOzh6N{[wOS=>
J82 NF;zbFRHfW6ldHnvckBie3OjeR?= MknsNlAh|ryP NWT0O4NCTE2VTx?= NF\Gb|lqdmS3Y3XzJIx6e2:|b33hcE1l\XCnbnTlcpQhdmWlcn;zbZM> NH6w[ngzOzh6N{[wOS=>
5637 NYTS[XRQTnWwY4Tpc44h[XO|YYm= MXqyNEDPxE1? NXq0[YF7TE2VTx?= MUPpcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 NWf2SWN1OjN6OEe2NFU>
J82 NEe3VpRHfW6ldHnvckBie3OjeR?= NWLJRpJEOjBizszN Mo[wSG1UVw>? NUjJOJZtcW6mdXPld{BtgXOxc3;t[UBidHSncnH0bY9vKGGwZDDpcohq[mm2czDDRkBi[3Srdnn0fS=> NH6weXUzOzh6N{[wOS=>
KATO-II MmHvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4m3SlUh|ryP MoX3SG1UVw>? MmrMZoxw[2u|IIDyc4xq\mW{YYTpc44> MmTHNlUzPDl3NUe=
OCUM-2M MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M13sZ|Uh|ryP M4DYNmROW09? MoTZZoxw[2u|IIDyc4xq\mW{YYTpc44> MYeyOVI1QTV3Nx?=
SNU-16 NVvsfJRxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVPXVlR5PSEQvF2= NYXkeJZvTE2VTx?= MUTicI9kc3NicILvcIln\XKjdHnvci=> M4r5OVI2OjR7NUW3
HSC-39 NWHCRpRuT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkLOOUDPxE1? MV7EUXNQ NVi4dIFX[myxY3vzJJBzd2yrZnXyZZRqd25? NWnCXZpYOjV{NEm1OVc>
KATO-II NWPle4Y3[3m2b4TvfIlkcXS7IHHzd4F6 NXzRUJFmhjFyIN88US=> NInE[lhFVVOR NG[3ZZdKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= M1PYN|I2OjR7NUW3
OCUM-2M NGrIVW5kgXSxdH;4bYNqfHliYYPzZZk> M4n3[J4yOCEQvF2= NWDZbJp4TE2VTx?= NFjVeXpKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= NFK3NGUzPTJ2OUW1Oy=>
SNU-16 MXvjfZRwfG:6aXPpeJkh[XO|YYm= NIjvOIt,OTBizszN NFvobo1FVVOR MlK1TWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? NV;0NHFXOjV{NEm1OVc>
HSC-39 MYHjfZRwfG:6aXPpeJkh[XO|YYm= NHvhSmh,OTBizszN MUHEUXNQ M3rVSGlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O MomzNlUzPDl3NUe=
NIH 3T3 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mnm2glExKM7:TR?= Mm\lSG1UVw>? MmXmbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W6mIHPvcI9vgSCob4LtZZRqd25? M{TDO|I2OjR7NUW3
KATO-III MVLGeY5kfGmxbjDhd5NigQ>? NV6yOIt3OSEQvF2= NVHiZ4UyTE2VTx?= MYnpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 NXLGZZNTOjV{NEm1OVc>
OCUM-2M NUjyNYc6TnWwY4Tpc44h[XO|YYm= NYTEc4pROSEQvF2= NYPkNIp3TE2VTx?= NGTWS5NqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 NYTYbWJtOjV{NEm1OVc>
KATO-III NGXCTJBCeG:ydH;zbZMh[XO|YYm= M{jnR|Eh|ryP NVf3bnBoTE2VTx?= NUHUUHlycW6mdXPld{BieG:ydH;zbZM> NXrOb3pEOjV{NEm1OVc>
OCUM-2M MU\BdI9xfG:|aYOgZZN{[Xl? MXOxJO69VQ>? MoDySG1UVw>? NFHicmVqdmS3Y3XzJIFxd3C2b4Ppdy=> MXuyOVI1QTV3Nx?=
KATO-III MlLYSpVv[3Srb36gZZN{[Xl? MVGxJO69VQ>? MVvEUXNQ MWjpcohq[mm2czDGS2ZTOiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nJI1wdGWldXzldy=> MXWyOVI1QTV3Nx?=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID